Pharmaceutical policy in Italy: towards a structural change?

Area of Science:

• Health Policy
• Pharmaceutical Economics
• Regulatory Affairs

Background:

• Italian pharmaceutical policy has adopted a "two lanes" regulatory approach, differentiating policies based on a drug's patent status.
• This framework specifically addresses the regulation of "off-patent" drugs, aiming to influence market dynamics and drug accessibility.
• Recent policy shifts reflect a move towards a more competitive landscape for pharmaceuticals once patent protection expires.

Purpose of the Study:

• To analyze the Italian regulatory framework for off-patent drugs.
• To examine the impact of key regulatory innovations on pharmaceutical market competition.
• To assess the effectiveness and sustainability of current policies governing generic and off-patent medications.

Main Methods:

• Analysis of the Italian regulatory framework concerning pharmaceutical policies.
• Examination of three specific regulatory innovations: generics, reference pricing (RP), and pharmacists' right of substitution.
• Evaluation of the competitive pressure generated by these reforms on off-patent drug substances.

Main Results:

• The introduction of generics in 1996 has been a significant development in the Italian market.
• The reference pricing (RP) scheme influences consumer cost-sharing for higher-priced products.
• Pharmacists' right of substitution, coupled with a regressive margins system, impacts drug dispensing and pricing.
• These reforms have demonstrably increased competitive pressure on the limited number of off-patent drugs.

Conclusions:

• Recent Italian pharmaceutical policy reforms have yielded positive results in fostering competition for off-patent drugs.
• The "two lanes" approach and associated innovations show promise in managing pharmaceutical markets.
• Further policy interventions may be necessary to ensure the long-term sustainability of these regulatory measures and their economic benefits.